{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:45:18Z","timestamp":1789854318320,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.euroneuro.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T09:42:30Z","timestamp":1469180550000},"page":"1412-1418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Mental disorder diagnoses among children and adolescents who use antipsychotic drugs"],"prefix":"10.1016","volume":"26","author":[{"given":"Ragnar","family":"Nesv\u00e5g","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Hartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen G.","family":"Bramness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidar","family":"Hjellvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte","family":"Handal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2016.07.001_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-244X-9-72","article-title":"Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data","volume":"9","author":"Acquaviva","year":"2009","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.001_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/070674371205700109","article-title":"Ten years of antipsychotic prescribing to children: a Canadian population-based study","volume":"57","author":"Alessi-Severini","year":"2012","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.001_bib3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.euroneuro.2014.11.003","article-title":"Present and future of developmental neuropsychopharmacology","volume":"25","author":"Arango","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.07.001_bib4","first-page":"25","article-title":"Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012","volume":"111","author":"Bachmann","year":"2014","journal-title":"Dtsch. \u00c4rzteblatt Int."},{"key":"10.1016\/j.euroneuro.2016.07.001_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pedhc.2011.10.009","article-title":"Antipsychotic medication prescribing trends in children and adolescents","volume":"26","author":"Harrison","year":"2012","journal-title":"J. Pediatr. Health Care"},{"key":"10.1016\/j.euroneuro.2016.07.001_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-0716-x","article-title":"Psychotropic drug use among 0\u201317 year olds during 2004\u20132014: a nationwide prescription database study","volume":"16","author":"Hartz","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.001_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/ps.2008.59.5.554","article-title":"Use of antipsychotic drugs among Dutch youths between 1997 and 2005","volume":"59","author":"Kalverdijk","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2016.07.001_bib8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.001_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/070674371205701202","article-title":"A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents","volume":"57","author":"Patten","year":"2012","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.001_bib10","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.euroneuro.2015.06.009","article-title":"Unmet needs in paediatric psychopharmacology: present scenario and future perspectives","volume":"25","author":"Persico","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.07.001_bib11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2016.07.001_bib12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0269881116636107","article-title":"BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents","volume":"30","author":"Sharma","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.07.001_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00787-014-0631-y","article-title":"Recent international trends in psychotropic medication prescriptions for children and adolescents","volume":"24","author":"Steinhausen","year":"2015","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.07.001_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/acps.12155","article-title":"Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark","volume":"129","author":"Steinhausen","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2016.07.001_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns","volume":"19","author":"Vitiello","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.07.001_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/cap.2009.0003","article-title":"Psychotropic drug use among Icelandic children: a nationwide population-based study","volume":"19","author":"Zoega","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16300992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16300992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T09:23:32Z","timestamp":1536571412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16300992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0924977X16300992"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.07.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mental disorder diagnoses among children and adolescents who use antipsychotic drugs","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}